Cargando…

Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial

The purpose of this study was to assess the pharmacokinetic (PK) characteristics, clinical efficiency, and pharmacoeconomic parameters of piperacillin/tazobactam administered by extended infusion (EI) or intermittent infusion (II) in the treatment of hospital-acquired pneumonia (HAP) in critically i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bao, H., Lv, Y., Wang, D., Xue, J., Yan, Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309263/ https://www.ncbi.nlm.nih.gov/pubmed/27796647 http://dx.doi.org/10.1007/s10096-016-2819-1

Ejemplares similares

Continuous versus intermittent administration of piperacillin–tazobactam in intensive care unit patients with ventilator-associated pneumonia
por: Fahimi, Fanak, et al.
Publicado: (2012)

Comparison of Cefepime with Piperacillin/Tazobactam Treatment in Patients with Hospital-Acquired Pneumonia
por: Kim, Bo-Guen, et al.
Publicado: (2023)

Piperacillin/tazobactam administered by continuous or intermittent infusion for the treatment of nosocomial pneumonia
por: Lorente, L, et al.
Publicado: (2009)

Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia
por: Chen, Chia-Hung, et al.
Publicado: (2021)

60. Evaluation of Outcomes Associated with Intermittent Versus Extended Infusion of Piperacillin/tazobactam in Acutely Ill Veterans
por: Encarnacion, Marianne Angeli, et al.
Publicado: (2020)

The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia
por: Lai, Chih-Cheng, et al.
Publicado: (2023)

Extended infusion of piperacillin–tazobactam versus intermittent infusion in critically ill egyptian patients: a cost-effectiveness study
por: Naiim, Christina Medhat, et al.
Publicado: (2022)

2805. Extended-Infusion versus Intermittent-Infusion Piperacillin/tazobactam for High Minimum Inhibitory Concentration Pseudomonas aeruginosa Infections
por: Shifko, Carlee R, et al.
Publicado: (2023)

Piperacillin/tazobactam: Eosinophilic-pneumonia: case report
Publicado: (2021)

Piperacillin/Tazobactam (ZOSYN)
por: Culver, Stephanie M., et al.
Publicado: (1996)

Piperacillin/tazobactam: Acute eosinophilic pneumonia: case report
Publicado: (2021)

1306. Comparison of the Use of Extended and Intermittent Infusion Cefepime and Piperacillin/tazobactam in Non-critically Ill, Obese Patients
por: Marg, Carolyn, et al.
Publicado: (2020)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
por: Yang, Jihyun, et al.
Publicado: (2023)

Selection of piperacillin/tazobactam infusion mode guided by SOFA score in cancer patients with hospital-acquired pneumonia: a randomized controlled study
por: Lyu, Yang, et al.
Publicado: (2017)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Pragmatic Comparison of Piperacillin/Tazobactam versus Carbapenems in Treating Patients with Nosocomial Pneumonia Caused by Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae
por: Zha, Lei, et al.
Publicado: (2022)

Clinical Benefits of Piperacillin/Tazobactam versus a Combination of Ceftriaxone and Clindamycin in the Treatment of Early, Non-Ventilator, Hospital-Acquired Pneumonia in a Community-Based Hospital
por: Park, Ga Eun, et al.
Publicado: (2020)

DRESS syndrome induced by piperacillin-tazobactam
por: Sanchez-Gonzalez, Maria-Jose, et al.
Publicado: (2014)

Rapid Detection of Piperacillin-Tazobactam Resistance in Klebsiella pneumoniae and Escherichia coli
por: Ortiz de la Rosa, José Manuel, et al.
Publicado: (2023)

2432. Appropriateness of Empiric Extended-Infusion Piperacillin/Tazobactam in the Intensive Care Unit
por: Tucker, Kendall, et al.
Publicado: (2018)

Is Piperacillin-Tazobactam an Appropriate Empirical Agent for Hospital-Acquired Sepsis and Community-Acquired Septic Shock of Unknown Origin in Australia?
por: Gage-Brown, Alice, et al.
Publicado: (2022)

Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
por: Ng, Tat Ming, et al.
Publicado: (2016)

Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin/Tazobactam: Are Extended Infusions to Blame?
por: Navalkele, Bhagyashri, et al.
Publicado: (2015)

2687. Extended Infusions of Piperacillin/Tazobactam vs. Cefepime for Empiric Treatment of Neutropenic Fever
por: Norman, Sarah, et al.
Publicado: (2019)

Enterobacter endophthalmitis: Treatment with intravitreal tazobactam- piperacillin
por: Singh, Trehan Hemant, et al.
Publicado: (2007)

Piperacillin-tazobactam-induced hypokalemia and metabolic alkalosis
por: Zaki, Syed Ahmed, et al.
Publicado: (2011)

Piperacillin–tazobactam as alternative to carbapenems for ICU patients
por: Pilmis, Benoit, et al.
Publicado: (2017)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

2893 B. Effect of Cefepime versus Piperacillin-Tazobactam in Adults Hospitalized with Acute Infection: A Randomized Clinical Trial
por: Qian, Edward, et al.
Publicado: (2023)

Pharmacokinetic/pharmacodynamic predictions and clinical outcomes of patients with augmented renal clearance and Pseudomonas aeruginosa bacteremia and/or pneumonia treated with extended infusion cefepime versus extended infusion piperacillin/tazobactam
por: Gerlach, Anthony T., et al.
Publicado: (2019)

212. Acute Kidney Injury with Piperacillin-tazobactam versus Cefepime in Combination with Vancomycin
por: Nguyen, Phuong Khanh, et al.
Publicado: (2020)

80. Pharmacoeconomic Analysis Comparing the Empiric Utilization of Cefepime Versus Piperacillin/tazobactam
por: Olmack, Kelsey, et al.
Publicado: (2020)

Efflux Pump AcrAB Confers Decreased Susceptibility to Piperacillin–Tazobactam and Ceftolozane–Tazobactam in Tigecycline-Non-Susceptible Klebsiella pneumoniae
por: Li, Junjie, et al.
Publicado: (2020)

Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials
por: An, Mao Mao, et al.
Publicado: (2009)

Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients
por: Felton, T W, et al.
Publicado: (2014)

Tazobactam and piperacillin-induced thrombocytopenia: A case report
por: CHEN, HONG, et al.
Publicado: (2016)

Piperacillin/Tazobactam as Cause of Acute Generalized Exanthematous Pustulosis
por: Kyriakou, Aikaterini, et al.
Publicado: (2019)

Meropenem/piperacillin/tazobactam: Drug resistance: case report
Publicado: (2021)

Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy
por: Workum, J D, et al.
Publicado: (2020)

Piperacillin/tazobactam/vancomycin: Cast nephropathy: case report
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_00aooqh7h5cb7mr4maksbel8b6